Frederick Banting

“Insulin does not belong to me, it belongs to the world.”

A discovery can belong to its discoverer in a history book and still carry obligations to people the discoverer will never meet. Frederick Banting’s statement about insulin expresses that distinction with unusual directness. The University of Toronto reproduces the quotation in its account of a symposium on insulin’s legacy, and the Canadian Medical Hall of Fame preserves the same wording in Banting’s profile. Its documented historical setting is the development of insulin treatment and the question of who should benefit from that work. These authoritative accounts support the attribution, although they do not establish the precise occasion on which the sentence was first spoken. The words should therefore be read as Banting’s recorded position within that history, without an invented conversation attached. The central idea is clear: personal achievement is not the final purpose of a medical advance. Its significance extends to the people whose lives depend on access to it.

That principle sits within a collaborative story. The Toronto work involved Banting, Charles Best, J. J. R. Macleod and James Collip, building on earlier research rather than creating knowledge from nothing. A historical review in the Journal of Clinical Investigation explains how the researchers confronted the practical relationship between patents, production and access. It describes transfer of patent rights by Banting, Best and Collip to the university for a nominal dollar each, and their concern that a competing monopoly could obstruct the work. This context complicates a familiar retelling in which generosity simply means abandoning every formal protection. The historical question was how to make a useful discovery available while navigating the institutions needed to produce it. The quotation gives that problem a moral direction without making the implementation simple. Recognition for scientific work and responsibility for its public use can coexist, even when arrangements for ownership demand difficult judgment.

For a reader today, the most useful word may be the one that enlarges the circle of concern beyond the laboratory. The world includes people far from research centers, people unfamiliar with the names in a discovery story, and people for whom a treatment’s availability is an everyday concern. A medicine celebrated as an achievement must still be manufactured, delivered and usable where it is needed. The sentence does not provide a complete pricing policy, promise universal availability, or settle every debate about medical innovation. It does ask whether the practical result matches the purpose that gives the innovation value. That question can shape how institutions describe success: not solely through a patent, prize or publication, but through the connection between discovery and care. Banting’s words invite gratitude for scientific contribution alongside scrutiny of who can benefit from it. The ethical reach of an achievement may be larger than the name attached to it.